A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Sponsor
Hoffmann-La Roche
Study ID
NCT01214720
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will evaluate efficacy, safety and tolerability of Avastin versus placebo added to a chemotherapeutic regimen in patients with metastatic pancreatic cancer. The anticipated time of study treatment is until confirmed evidence of disease progression, and the target sample size is 500+ individuals.

Key Dates

First listed
Oct 5, 2010
Start date
Jul 31, 2005
Status verified
Jul 2014
Primary completion
Oct 31, 2008
Completion
Oct 31, 2008

Study Design

Enrollment
607 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Duration of Overall Survival - Percentage of Participants With an Event [ Time Frame: Randomization, Weeks 1-8 of Cycle 1, Weeks 1-3 of consecutive cycles, 28 days and 3 months after lst treatment, and every 3 months for up to 18 months from last participant randomized ]

Related Studies